Medizinische Universität Graz - Research portal

Navigation/Search

• Researchers.
• Institutions.
• Projects.
• Publications.
• Partners.
• Sponsors.
• Equipment.
• Knowhow.
• Fields of Research.

Publications

Search Items: MELANOMA - DRUG THERAPY , . hits: 71

2022

Dankner, M; Wang, Y; Fazelzad, R; Johnson, B; Nebhan, CA; Dagogo-Jack, I; Myall, NJ; Richtig, G; Bracht, JWP; Gerlinger, M; Shinozaki, E; Yoshino, T; Kotani, D; Fangusaro, JR; Gautschi, O; Mazieres, J; Sosman, JA; Kopetz, S; Subbiah, V; Davies, MA; Groover, AL; Sullivan, RJ; Flaherty, KT; Johnson, DB; Benedetti, A; Cescon, DW; Spreafico, A; Zogopoulos, G; Rose, AAN Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors.
JCO Precis Oncol. 2022; 6:e2200107 Doi: 10.1200/PO.22.00107
Web of Science PubMed FullText FullText_MUG

 

2021

Corneli, P; Moscarella, E; DI, Brizzi, EV; Donadio, C; Zalaudek, I; Alfano, R; Argenziano, G Serial excision and imiquimod for lentigo maligna melanoma: a proposal for a combined treatment.
Ital J Dermatol Venerol. 2021; 156(Suppl. 1 to No. 6):3-4 Doi: 10.23736/S2784-8671.18.06168-0
Web of Science PubMed FullText FullText_MUG

 

Kretschmer, N; Hufner, A; Durchschein, C; Popodi, K; Rinner, B; Lohberger, B; Bauer, R Synthesis and Pharmacological In Vitro Investigations of Novel Shikonin Derivatives with a Special Focus on Cyclopropane Bearing Derivatives.
Int J Mol Sci. 2021; 22(5): Doi: 10.3390/ijms22052774 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2018

Durchschein, C; Hufner, A; Rinner, B; Stallinger, A; Deutsch, A; Lohberger, B; Bauer, R; Kretschmer, N Synthesis of Novel Shikonin Derivatives and Pharmacological Effects of Cyclopropylacetylshikonin on Melanoma Cells.
Molecules. 2018; 23(11): Doi: 10.3390/molecules23112820 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Kretschmer, N; Deutsch, A; Durchschein, C; Rinner, B; Stallinger, A; Higareda-Almaraz, JC; Scheideler, M; Lohberger, B; Bauer, R Comparative Gene Expression Analysis in WM164 Melanoma Cells Revealed That β-β-Dimethylacrylshikonin Leads to ROS Generation, Loss of Mitochondrial Membrane Potential, and Autophagy Induction.
Molecules. 2018; 23(11): Doi: 10.3390/molecules23112823 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Menzer, C; Beedgen, B; Rom, J; Duffert, CM; Volckmar, AL; Sedlaczek, O; Richtig, E; Enk, A; Jäger, D; Hassel, JC Immunotherapy with ipilimumab plus nivolumab in a stage IV melanoma patient during pregnancy.
Eur J Cancer. 2018; 104(2):239-242 Doi: 10.1016/j.ejca.2018.09.008 (- Case Report)
Web of Science PubMed FullText FullText_MUG

 

Richtig, G; Hoeller, C; Wolf, M; Wolf, I; Rainer, BM; Schulter, G; Richtig, M; Grübler, MR; Gappmayer, A; Haidn, T; Kofler, J; Huegel, R; Lange-Asschenfeldt, B; Pichler, M; Pilz, S; Heinemann, A; Richtig, E Body mass index may predict the response to ipilimumab in metastatic melanoma: An observational multi-centre study.
PLoS One. 2018; 13(10):e0204729-e0204729 Doi: 10.1371/journal.pone.0204729 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2017

Petrella, TM; Robert, C; Richtig, E; Miller, WH; Masucci, GV; Walpole, E; Lebbe, C; Steven, N; Middleton, MR; Hille, D; Zhou, W; Ibrahim, N; Cebon, J Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.
EUR J CANCER. 2017; 86(5): 115-124. Doi: 10.1016/j.ejca.2017.08.032 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2016

Eigentler, TK; Gutzmer, R; Hauschild, A; Heinzerling, L; Schadendorf, D; Nashan, D; Hölzle, E; Kiecker, F; Becker, J; Sunderkötter, C; Moll, I; Richtig, E; Pönitzsch, I; Pehamberger, H; Kaufmann, R; Pföhler, C; Vogt, T; Berking, C; Praxmarer, M; Garbe, C; Dermatologic Cooperative Oncology Group (DeCOG) Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial.
Ann Oncol. 2016; 27(8):1625-1632 Doi: 10.1093/annonc/mdw225 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Lee, SB; Weide, B; Ugurel, S; Mössner, R; Enk, A; Hassel, JC Vemurafenib-induced granuloma annulare.
J Dtsch Dermatol Ges. 2016; 14(3):305-308 Doi: 10.1111/ddg.12777 (- Case Report)
Web of Science PubMed FullText FullText_MUG

 

2015

Obenauf, AC; Zou, Y; Ji, AL; Vanharanta, S; Shu, W; Shi, H; Kong, X; Bosenberg, MC; Wiesner, T; Rosen, N; Lo, RS; Massagué, J Therapy-induced tumour secretomes promote resistance and tumour progression.
Nature. 2015; 520(7547): 368-372. Doi: 10.1038/nature14336 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Ravindran Menon, D; Das, S; Krepler, C; Vultur, A; Rinner, B; Schauer, S; Kashofer, K; Wagner, K; Zhang, G; Bonyadi Rad, E; Haass, NK; Soyer, HP; Gabrielli, B; Somasundaram, R; Hoefler, G; Herlyn, M; Schaider, H A stress-induced early innate response causes multidrug tolerance in melanoma.
Oncogene. 2015; 34(34):4448-4459 Doi: 10.1038/onc.2014.372 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Robert, C; Schachter, J; Long, GV; Arance, A; Grob, JJ; Mortier, L; Daud, A; Carlino, MS; McNeil, C; Lotem, M; Larkin, J; Lorigan, P; Neyns, B; Blank, CU; Hamid, O; Mateus, C; Shapira-Frommer, R; Kosh, M; Zhou, H; Ibrahim, N; Ebbinghaus, S; Ribas, A; KEYNOTE-006 investigators Pembrolizumab versus Ipilimumab in Advanced Melanoma.
N Engl J Med. 2015; 372(26):2521-2532 Doi: 10.1056/NEJMoa1503093 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Ugurel, S; Loquai, C; Kähler, K; Hassel, J; Berking, C; Zimmer, L; Haubitz, I; Satzger, I; Müller-Brenne, T; Mikhaimer, NC; Becker, JC; Kilian, KJ; Schadendorf, D; Heinzerling, L; Kaatz, M; Utikal, J; Göppner, D; Pföhler, C; Pflugfelder, A; Mössner, R; Gutzmer, R; Dermatologic Cooperative Oncology Group (DeCOG) A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival.
Ann Oncol. 2015; 26(3):573-582 Doi: 10.1093/annonc/mdu573 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2014

Goldinger, SM; Zimmer, L; Schulz, C; Ugurel, S; Hoeller, C; Kaehler, KC; Schadendorf, D; Hassel, JC; Becker, J; Hauschild, A; Dummer, R; Dermatology Cooperative Oncology Group (DeCOG) Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.
Eur J Cancer. 2014; 50(2):406-410 Doi: 10.1016/j.ejca.2013.09.014
Web of Science PubMed FullText FullText_MUG

 

Niederkorn, A; Wackernagel, W; Artl, M; Schwantzer, G; Aigner, B; Richtig, E Response of patients with metastatic uveal melanoma to combined treatment with fotemustine and sorafenib.
Acta Ophthalmol. 2014; 92(8):e696-e697 Doi: 10.1111/aos.12432 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Riedl, S; Rinner, B; Schaider, H; Lohner, K; Zweytick, D Killing of melanoma cells and their metastases by human lactoferricin derivatives requires interaction with the cancer marker phosphatidylserine.
Biometals. 2014; 27(5):981-997 Doi: 10.1007/s10534-014-9749-0 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Schrama, D; Groesser, L; Ugurel, S; Hafner, C; Pastrana, DV; Buck, CB; Cerroni, L; Theiler, A; Becker, JC Presence of human polyomavirus 6 in mutation-specific BRAF inhibitor-induced epithelial proliferations.
JAMA Dermatol. 2014; 150(11):1180-1186 Doi: 10.1001/jamadermatol.2014.1116 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Weide, B; Eigentler, TK; Pflugfelder, A; Zelba, H; Martens, A; Pawelec, G; Giovannoni, L; Ruffini, PA; Elia, G; Neri, D; Gutzmer, R; Becker, JC; Garbe, C Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses.
Cancer Immunol Res. 2014; 2(7):668-678 Doi: 10.1158/2326-6066.CIR-13-0206 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2013

Aigner, B; Richtig, E; Becker, JC; Lingitz, H; Niederkorn, RMA; Ugurel, S; Partial Response of Metastatic Mucosal Melanoma After Palliative Chemotherapy With Trofosfamide: A Case Report.
J Clin Oncol. 2013; 31(2):e31-e32 Doi: 10.1200/JCO.2012.44.2053 (- Case Report) [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Becker, JC; Schrama, D; The Dark Side of Cyclophosphamide: Cyclophosphamide-Mediated Ablation of Regulatory T Cells.
J INVEST DERMATOL. 2013; 133(6): 1462-1465. Doi: 10.1038/jid.2013.67 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Degen, A; Weichenthal, M; Ugurel, S; Trefzer, U; Kilian, K; Garbe, C; Egberts, F; Poppe, LM; Hauschild, A; Gutzmer, R Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha-2b in metastatic melanoma (phase II DeCOG trial).
J Dtsch Dermatol Ges. 2013; 11(9):846-853 Doi: 10.1111/ddg.12100
Web of Science PubMed FullText FullText_MUG

 

Kruit, WH; Suciu, S; Dreno, B; Mortier, L; Robert, C; Chiarion-Sileni, V; Maio, M; Testori, A; Dorval, T; Grob, JJ; Becker, JC; Spatz, A; Eggermont, AM; Louahed, J; Lehmann, FF; Brichard, VG; Keilholz, U Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma.
J Clin Oncol. 2013; 31(19): 2413-2420. Doi: 10.1200/JCO.2012.43.7111 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

O'Day, SJ; Eggermont, AMM; Chiarion-Sileni, V; Kefford, R; Grob, JJ; Mortier, L; Robert, C; Schachter, J; Testori, A; Mackiewicz, J; Friedlander, P; Garbe, C; Ugurel, S; Collichio, F; Guo, W; Lufkin, J; Bahcall, S; Vukovic, V; Hauschild, A; Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced Melanoma.
J Clin Oncol. 2013; 31(9):1211-1218 Doi: 10.1200/JCO.2012.44.5585 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Richtig, E; Schrama, D; Ugurel, S; Fried, I; Niederkorn, A; Massone, C; Becker, JC BRAF mutation analysis of only one single metastatic lesion can restrict the treatment of melanoma - a case report.
Br J Dermatol. 2013; 168(2):428-430 Doi: 10.1111/j.1365-2133.2012.11121.x (- Case Report)
Web of Science PubMed FullText FullText_MUG

 

2012

Flaherty, KT; Robert, C; Hersey, P; Nathan, P; Garbe, C; Milhem, M; Demidov, LV; Hassel, JC; Rutkowski, P; Mohr, P; Dummer, R; Trefzer, U; Larkin, JMG; Utikal, J; Dreno, B; Nyakas, M; Middleton, MR; Becker, JC; Casey, M; Sherman, LJ; Wu, FS; Ouellet, D; Martin, AM; Patel, K; Schadendorf, D; Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma.
N ENGL J MED. 2012; 367(2): 107-114. Doi: 10.1056/NEJMoa1203421 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2011

Egberts, F; Gutzmer, R; Ugurel, S; Becker, JC; Trefzer, U; Degen, A; Schenck, F; Frey, L; Wilhelm, T; Hassel, JC; Schadendorf, D; Livingstone, E; Mauch, C; Garbe, C; Berking, C; Rass, K; Mohr, P; Kaehler, KC; Weichenthal, M; Hauschild, A Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial.
Ann Oncol. 2011; 22(7):1667-1674 Doi: 10.1093/annonc/mdq648 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Tiodorovic-Zivkovic, D; Argenziano, G; Catricalà, C; Ferrara, G; Giorgio, CM; Moscarella, E; Zalaudek, I Adjuvant treatment with topical 5% imiquimod cream for resected stage IIIb melanoma.
Eur J Dermatol. 2011; 21(3):410-411 Doi: 10.1684/ejd.2011.1282 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Ugurel, S Chemotherapy in metastatic melanoma - still useful or out of date?
Onkologie. 2011; 34(4):159-160 Doi: 10.1159/000327314 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Ugurel, S; Becker, JC [Treatment of advanced metastatic melanoma].
Hautarzt. 2011; 62(6):423-429 Doi: 10.1007/s00105-010-2041-5
Web of Science PubMed FullText FullText_MUG

 

2010

Terheyden, P; Houben, R; Pajouh, P; Thorns, C; Zillikens, D; Becker, JC Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene.
J Invest Dermatol. 2010; 130(1):314-316 Doi: 10.1038/jid.2009.197 (- Case Report) [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2009

Agarwala, SS; Becker, JC; Eggermont, AM; Flaherty, KT; Garbe, C; Goldstein, AM; Halpern, A; Kashani-Sabet, M; Hauschild, A; Kirkwood, JM; Leachman, S; Lorigan, P; McMahon, M; Messina, J; Ribas, A; Samlowski, WE; Schadendorf, D; Sondak, VK Meeting report: consensus from the first and second Global Workshops in Melanoma November 19-20, 2008.
Pigment Cell Melanoma Res. 2009; 22(5):532-543 Doi: 10.1111/j.1755-148X.2009.00602.x
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Hofmann, UB; Kauczok-Vetter, CS; Houben, R; Becker, JC Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate.
Clin Cancer Res. 2009; 15(1):324-329 Doi: 10.1158/1078-0432.CCR-08-2243 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2008

Hauschild, A; Dummer, R; Ugurel, S; Kaehler, KC; Egberts, F; Fink, W; Both-Skalsky, J; Laetsch, B; Schadendorf, D Combined treatment with pegylated interferon-alpha-2a and dacarbazine in patients with advanced metastatic melanoma: a phase 2 study.
Cancer. 2008; 113(6):1404-1411 Doi: 10.1002/cncr.23722 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Hauschild, A; Trefzer, U; Garbe, C; Kaehler, KC; Ugurel, S; Kiecker, F; Eigentler, T; Krissel, H; Schott, A; Schadendorf, D Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma.
Melanoma Res. 2008; 18(4):274-278 Doi: 10.1097/CMR.0b013e328307c248
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Houben, R; Wischhusen, J; Menaa, F; Synwoldt, P; Schrama, D; Brocker, EB; Becker, JC Melanoma stem cells: targets for successful Therapy?
J DTSCH DERMATOL GES. 2008; 6(7): 541-547. Doi: 10.1111/j.1610-0387.2008.06786.x
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Schrama, D; Hauschild, A; Becker, JC Immunmodulatory antibodies in the treatment of skin cancer
Hautarzt. 2008; 59(10):806-813 Doi: 10.1007/s00105-008-1539-6
Web of Science PubMed FullText FullText_MUG

 

Spieth, K; Kaufmann, R; Dummer, R; Garbe, C; Becker, JC; Hauschild, A; Tilgen, W; Ugurel, S; Beyeler, M; Bröcker, EB; Kaehler, KC; Pföhler, C; Gille, J; Leiter, U; Schadendorf, D Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Ann Oncol. 2008; 19(4):801-806 Doi: 10.1093/annonc/mdm565 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Ugurel, S In vitro drug sensitivity profiling in melanoma.
J Dtsch Dermatol Ges. 2008; 6(7):611-611 Doi: 10.1111/j.1610-0387.2008.06804.x
PubMed FullText FullText_MUG

 

2007

Becker, JC; Brocker, EB; Schadendorf, D; Ugurel, S Imatinib in melanoma: a selective treatment option based on KIT mutation status?
J Clin Oncol. 2007; 25(7):e9-e9 Doi: 10.1200/JCO.2006.08.9664 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Terheyden, P; Hofmann, MA; Weininger, M; Brocker, EB; Becker, JC Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanoma.
J Cancer Res Clin Oncol. 2007; 133(11):897-901 Doi: 10.1007/s00432-007-0251-8 (- Case Report)
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Wolf, IH; Kodama, K; Cerroni, L; Kerl, H Nature of inflammatory infiltrate in superficial cutaneous malignancies during topical imiquimod treatment.
Am J Dermatopathol. 2007; 29(3):237-241 Doi: 10.1097/01.dad.0000211531.33670.94
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2006

Becker, JC; Kirkwood, JM; Agarwala, SS; Dummer, R; Schrama, D; Hauschild, A Molecularly targeted therapy for melanoma: current reality and future options.
Cancer. 2006; 107(10):2317-2327 Doi: 10.1002/cncr.22273 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Becker, JC; Ugurel, S; Bröcker, EB; Schrama, D; Houben, R New therapeutic approaches for solid tumors: histone deacetylase, methyltransferase and proteasome inhibitors.
J Dtsch Dermatol Ges. 2006; 4(2):108-113 Doi: 10.1111/j.1610-0387.2006.05920.x
PubMed FullText FullText_MUG Google Scholar

 

Richtig, E; Langmann, G; Schlemmer, G; Müllner, K; Papaefthymiou, G; Bergthaler, P; Smolle, J Safety and efficacy of interferon alfa-2b in the adjuvant treatment of uveal melanoma
OPHTHALMOLOGE. 2006; 103(6): 506-511. Doi: 10.1007/s00347-006-1350-7
Web of Science PubMed FullText FullText_MUG

 

Schadendorf, D; Hauschild, A; Ugurel, S; Thoelke, A; Egberts, F; Kreissig, M; Linse, R; Trefzer, U; Vogt, T; Tilgen, W; Mohr, P; Garbe, C Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study.
Ann Oncol. 2006; 17(10):1592-1597 Doi: 10.1093/annonc/mdl148 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Ugurel, S; Schadendorf, D; Pföhler, C; Neuber, K; Thoelke, A; Ulrich, J; Hauschild, A; Spieth, K; Kaatz, M; Rittgen, W; Delorme, S; Tilgen, W; Reinhold, U; Dermatologic Cooperative Oncology Group In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group.
Clin Cancer Res. 2006; 12(18):5454-5463 Doi: 10.1158/1078-0432.CCR-05-2763 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Utikal, J; Zimpfer, A; Thoelke, A; Figl, R; Hildenbrand, R; Kettelhack, C; Goerdt, S; Schadendorf, D; Ugurel, S Complete remission of multiple satellite and in-transit melanoma metastases after sequential treatment with isolated limb perfusion and topical imiquimod.
Br J Dermatol. 2006; 155(2):488-491 Doi: 10.1111/j.1365-2133.2006.07333.x (- Case Report)
Web of Science PubMed FullText FullText_MUG

 

2005

Andersen, MH; Reker, S; Stratem, PT; Gehl, J; Geertsen, P; Becker, JC Concomitant administration of interleukin-2 during therapeutic vaccinations against cancer: the good, the bad, or the evil?
J Clin Oncol. 2005; 23(22):5265-5267 Doi: 10.1200/JCO.2004.00.9837 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Becker, JC; Schrama, D; Bröcker, EB; Houben, R Kinase inhibitors for the therapy of malignant melanoma
J Dtsch Dermatol Ges. 2005; 3(10):762-767 Doi: 10.1111/j.1610-0387.2005.05016.x
PubMed FullText FullText_MUG

 

Show the next 50 results of search

↑ Top of page / Navigation

© Med Uni Graz • Imprint